The Netherlands Cancer Institute

Researchers

• RFRemond J A Fijneman

Running trials

• Recruiting

  Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

  NCT07436858· Phase 1· The Netherlands Cancer Institute· Source

• Recruiting

  Phase 1 Study of PF-08046033 in Advanced Solid Tumors

  NCT07519655· Phase 1· Pfizer· Source

• Recruiting

  A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

  NCT07535112· Phase 1· Bayer· Source

• Recruiting

  PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).

  2025-523781-25-00· Phase 1· CimCure B.V.· Source

• Recruiting

  Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

  NCT07472868· Phase 3· Catharina Ziekenhuis Stichting· Source

• Not yet recruiting

  IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

  2025-521908-22-00· Phase 2/3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas

  NCT07071727· The Netherlands Cancer Institute· Source

• Recruiting

  Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions

  NCT07391982· The Netherlands Cancer Institute· Source

• Recruiting

  TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

  NCT06931769· The Netherlands Cancer Institute· Source

• Recruiting

  Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

  NCT07100730· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source

• Recruiting

  Contrast-enhanced Ultrasound for Sentinel Node Detection

  NCT07310758· Phase 2/3· The Netherlands Cancer Institute· Source

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source

• Recruiting

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· Phase 1/2· Alentis Therapeutics AG· Source

• Recruiting

  Prospective Data Collection Initiative on Thoracic Malignancies

  NCT06996249· Dutch Society of Physicians for Pulmonology and Tuberculosis· Source

• Recruiting

  [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

  NCT07018661· Phase 2/3· Leiden University Medical Center· Source

• Recruiting

  Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  NCT06486883· Phase 2· MedSIR· Source

• Recruiting

  Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

  NCT06960577· Phase 2· AstraZeneca· Source

• Recruiting

  The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

  NCT07460180· Phase 1/2· The Netherlands Cancer Institute· Source

• Recruiting

  Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

  NCT06401824· Phase 2· Maastricht University Medical Center· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  NCT06914128· Phase 1/2· Bayer· Source

• Recruiting

  The Radium-select Study

  NCT06659926· The Netherlands Cancer Institute· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer

  NCT06568679· The Netherlands Cancer Institute· Source

• Enrolling by invitation

  Automated Detection of Brain Metastases on MRI

  NCT06727032· Robovision BV· Source

• Recruiting

  First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

  NCT06644755· Phase 1· Daiichi Sankyo· Source

• Not yet recruiting

  Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)

  2024-512318-16-00· Phase 2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

  NCT06567015· Phase 1/2· Pierre Fabre Medicament· Source

• Recruiting

  Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

  NCT07377747· Australia and New Zealand Sarcoma Association· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

  NCT06082492· Radboud University Medical Center· Source

• Recruiting

  PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)

  NCT06875258· Phase 4· The Netherlands Cancer Institute· Source

• Recruiting

  Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.

  NCT05333523· Phase 3· Radboud University Medical Center· Source

• Recruiting

  Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm

  NCT05779631· Radboud University Medical Center· Source

• Active, not recruiting

  Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

  NCT05607550· Phase 3· ArriVent BioPharma, Inc.· Source

• Active, not recruiting

  Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer

  NCT05705921· The Netherlands Cancer Institute· Source

• Active, not recruiting

  Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

  NCT05131919· Phase 2· The Netherlands Cancer Institute· Source

• Not yet recruiting

  Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy

  NCT05373316· Phase 2· Radboud University Medical Center· Source

• Recruiting

  Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

  NCT05522660· Phase 3· ETOP IBCSG Partners Foundation· Source

• Recruiting

  A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  NCT05208762· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy

  NCT04711330· Leiden University Medical Center· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

  NCT05384626· Phase 1/2· Nuvalent Inc.· Source

• Active, not recruiting

  Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

  NCT05148546· Phase 2· The Netherlands Cancer Institute· Source

• Recruiting

  The Prognostic Role of Lymph Node Dissection In Men With Prostate Cancer Treated With Radical Prostatectomy

  NCT05109910· The Netherlands Cancer Institute· Source

• Recruiting

  Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

  NCT05255653· Phase 3· Leiden University Medical Center· Source

• Active, not recruiting

  Induction Chemotherapy for Locally Advanced Rectal Cancer

  NCT04838496· Phase 2· Catharina Ziekenhuis Eindhoven· Source

Showing 50 of 77.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer15 recruiting
• Colorectal cancer10 recruiting
• Bladder cancer6 recruiting
• Prostate cancer6 recruiting
• Gastric and oesophageal cancer5 recruiting
• Head and neck cancer4 recruiting
• Melanoma4 recruiting
• Sarcoma4 recruiting
• Brain metastases3 recruiting
• Childhood cancers3 recruiting
• Liver and biliary tract cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Pancreatic cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Endometrial cancer2 recruiting
• Glioblastoma2 recruiting
• Kidney cancer1 recruiting
• Mesothelioma1 recruiting
• Ovarian cancer1 recruiting
• Thymoma and thymic carcinoma1 recruiting

Closed trials

• Completed

  A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors

  2024-514745-10-00· Phase 1· Pfizer Inc.· Source

• Completed

  A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.

  NCT06173505· Phase 1/2· Xencor Inc.· Source

• Completed

  Navigated Partial Nephrectomy

  NCT07315100· The Netherlands Cancer Institute· Source

• Withdrawn

  JDQ443 for KRAS G12C NSCLC Brain Metastases

  NCT05999357· Phase 2· Maastricht University Medical Center· Source

• Completed

  A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL

  NCT06284304· The Netherlands Cancer Institute· Source

• Active, not recruiting

  Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

  NCT05853575· Phase 2· Mirati Therapeutics Inc.· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

  NCT05383170· Phase 1/2· Cytovation AS· Source

• Completed

  A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation

  NCT05480865· Phase 1· Navire Pharma Inc.· Source

• Active, not recruiting

  Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

  NCT05491616· Phase 2· Erasmus Medical Center· Source

• Completed

  Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

  NCT05458856· Phase 3· Ipsen· Source

• Completed

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· Phase 3· Bristol Myers Squibb International Corporation· Source

• Terminated

  Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

  NCT04908956· Phase 2· ETOP IBCSG Partners Foundation· Source

• Active, not recruiting

  HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

  NCT05338970· Phase 3· Daiichi Sankyo· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Multispectral Fluorescence as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies in Prostate Cancer.

  NCT05120973· The Netherlands Cancer Institute· Source

• Completed

  MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

  NCT04826003· Phase 1· Hoffmann-La Roche· Source

• Terminated

  (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

  NCT04862780· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  Threedimensional Multiparametric Ultrasound for Prostate Cancer Detection

  NCT04605276· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

• Completed

  Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

  NCT04925284· Phase 1· Exelixis· Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Phase 1/2· Merus B.V.· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT04644237· Phase 2· Daiichi Sankyo· Source

• Active, not recruiting

  HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

  NCT04619004· Phase 2· Daiichi Sankyo· Source

• Completed

  A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  NCT03906071· Phase 3· Mirati Therapeutics Inc.· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

  NCT04625205· Phase 1· Biontech US Inc.· Source

• Completed

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· Phase 3· GlaxoSmithKline· Source

• Terminated

  Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

  NCT04261777· Phase 3· Saving Patients' Lives Medical B.V.· Source

• Active, not recruiting

  A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

  NCT04211337· Phase 3· Loxo Oncology, Inc.· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Amgen· Source

• Completed

  Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

  NCT03945773· Phase 2· Ipsen· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

  NCT05993299· Phase 2· USWM, LLC (dba US WorldMeds)· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

  NCT06703346· Phase 2· USWM CT, LLC· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Active, not recruiting

  Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

  NCT03970746· Phase 1/2· PDC*line Pharma SAS· Source

• Active, not recruiting

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· Phase 3· Bristol-Myers Squibb· Source

• Completed

  An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

  NCT03915951· Phase 2· Pfizer· Source

• Terminated

  IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

  NCT03705403· Phase 2· Maastricht University Medical Center· Source

• Terminated

  Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

  NCT04287894· Phase 1· The Netherlands Cancer Institute· Source

• Completed

  A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

  NCT03661320· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Study to Evaluate CCS1477 in Advanced Tumours

  NCT03568656· Phase 1/2· CellCentric Ltd.· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Terminated

  DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

  NCT03505710· Phase 2· Daiichi Sankyo· Source

• Completed

  Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

  NCT03075423· Phase 2· Goethe University· Source

• Completed

  A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  NCT03267316· Phase 1/2· Cantargia AB· Source

• Completed

  Melanoma Patients Immunized with Natural DenDritic Cells

  NCT02993315· Phase 3· Radboud University Medical Center· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Pfizer· Source

• Completed

  Vascular Fingerprint Validation Study

  NCT02573584· University Medical Center Groningen· Source

• Completed

  Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

  NCT02278887· Phase 3· The Netherlands Cancer Institute· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Showing 50 of 51.

Conditions

Diseases this institution publishes on or runs trials for.

• Lung cancer100 works · 44 trials
• Prostate cancer87 works · 17 trials
• Melanoma78 works · 12 trials
• Colorectal cancer74 works · 21 trials
• Bladder cancer68 works · 8 trials
• Ovarian cancer44 works · 6 trials
• Sarcoma43 works · 9 trials
• Kidney cancer34 works · 8 trials
• Triple-negative breast cancer27 works · 8 trials
• Brain metastases19 works · 4 trials
• Endometrial cancer19 works · 4 trials
• Metastatic breast cancer16 works · 6 trials
• Head and neck cancer15 works · 10 trials
• Mesothelioma14 works · 1 trial
• Hodgkin lymphoma11 works · 1 trial
• Thyroid cancer9 works · 2 trials
• Testicular cancer3 works · 2 trials